http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
연속적으로 시행한 공장 근로자 건강 검진에서 무증상 간기능 검사 이상자의 임상적 특성
김강모,김윤준,이광혁,백도명,Kim, Gang-Mo,Kim, Yun-Jun,Lee, Gwang-Hyeok,Baek, Do-Myeong 한국건강관리협회 2005 한국건강관리협회지 Vol.3 No.2
Background/Aims The liver funtion tests(LFTs), such as aspartate aminotransferase(AST), alanine amino-transferase(ALT), r -glutamyl transferase( r -GT), have been widely used for screening tests but their low positive predictive value can cause many false positive results. To evaluate the clinical usefulness of these tests, we analyzed serial LFT results of single factory workers and compared the risk factor's in groups divided by the serial LFT results. Methods From June 2001 to October 2001, 1223 consecutive healthy workers in a single factory were enrolled and questionnaire, LFT and liver ultrasonography were performed. Previous LFT results were collected from Annual Health Examination Survey. According to the abnormalities in serial LFT, participants were classified into three groups (abnormal-in-both, alternating normal-in-both) and the risk factors were compared among these groups using multiple logistic regression Results The prevalence of LFT abnormality in a single test was 16.8% but, in serial LFT, only 5% of participants showed consistent abnormality. The risk factors for abnormal-in-both group, compared with alternating group, were liver ultrasonography abnormality such as fatty liver(odds ratio, 2.2; p=0.026) and heavy alcohol intake (more than 210g/week) (odds ratio, 7.2;P=0.064). HBsAg was not significant risk factor for any of the three groups. ConclusionIn factory workers with serial LFT abnormality, alcoholic liver disease could be the principal cause of abnormal LFT. Even if HBsAg were positive in patients with abnormal LFT, there is a possibility of another causes for LFT abnormalities such as alcoholic liver disease and nonalcoholic steatosis or steatohepatitis
박장원 ( Jang Won Park ),김강모 ( Gang Mo Kim ) 대한간암학회 2013 대한간암학회지 Vol.13 No.1
RT is an effective local therapy that has the potential to benefit patients unsuitable for and/or at high risk of complication following standard local-regional therapies. All of the following have facilitated the safe delivery of tumorcidal doses to focal HCCs using conformal RT: advances in imaging, RT planning techniques, image-guided radiotherapy, tumor immobilization, and improved knowledge of what volume of liver is required to be spared from radiation to preserve function. SBRT has more recently been used to treat focal HCC. SBRT is widely available and more convenient for patients than conventionally fractionated RT, as it is delivered in far fewer fractions than standard fractionated RT. We report our experience for a patient treated successfully with SBRT.
Doxorubicin-eluting beads를 이용한 TACE 후 추적관찰 전산화단층촬영에서 관찰된 비전형적인 1예
박장원 ( Jang Won Park ),김강모 ( Gang Mo Kim,) 대한간암학회 2012 대한간암학회지 Vol.12 No.2
Hepatocellular carcinoma is the sixth most common cancer and the third leading cause of cancer-ralated death. TACE is an effective option for patients with intermediate HCC. Although conventional TACE with administration of a Lipiodo-anticancer emulsion followed by embolic agents has been most popular technique, the recent introduction of embolic DEB has provided a valuable alternative. The DEB is a novel drug delivery embolization system that hea been designed to deliver a higher and more sustained release of drug directly into the tumor and a low release of drug into the systemic circulation, with the intention to maximize the drug effectiveness in terms of response, while significantly reducing its systemic toxicity. Obtaining a triple-phase CT or MRI imaging of the liver is required to integrate clinical and laboratory data to evaluate the indication to TACE with DEB and additional imaging to exclude extrahepatic disease should be performed as pretreatment imaging. Obtaining a CT or MRI imaging 2-4 weeks after TACE is recommend to assess tumor response and to decide the further plan. The use of modified Response Evaluation Criteria in Solid Tumors (mRECIST) for HCC is recommended for response Classification. We offer our experience of a patient with atypical finindg on follow-up CT after DEB TACE. Marginal recurrence or residual viable tumor was suspected on CT 4 weeks after DEB TACE but disappeared on CT 10 weeks after treatment. There was no evidence of recurrence or residual tumor in TACE site and its margin 12 weeks after TACE. We thought that it was attributed to the benign change as AV shunt or to the characteristics of DEB which has been designed to deliver slowly, higher and more sustained release of drug directly into the tumor. But further study is necessary on how long the drug delivery from DEB to tumor is sustained and when the appropriate tumor response is accomplished after treatment.
한국인 간세포암 환자에서 경피적 에탄올 주입술의 치료 효과
강현우 ( Kang Hyeon U ),김윤준 ( Kim Yun Jun ),김강모 ( Kim Gang Mo ),강정묵 ( Kang Jeong Mug ),김수환 ( Kim Su Hwan ),김진현 ( Kim Jin Hyeon ),윤원재 ( Yun Won Jae ),윤정환 ( Yun Jeong Hwan ),윤용범 ( Yun Yong Beom ),이효석 ( Lee 대한소화기학회 2003 대한소화기학회지 Vol.42 No.6
Background/Aims: Percutaneous ethanol injection therapy (PEIT) is widely used for the treatment of hepatocellular carcinoma (HCC). However, its long-term therapeutic efficacy is not verified in Korea, one of hepatitis B virus (HBV) endemic areas. Thus, this study was to assess its efficacy and prognostic factors affecting tumor-free survival following PEIT in Korean HCC patients. Methods: From 1997 to 1999, 100 consecutive patients who had 1 to 3 HCC nodules of maximum diameter less than 3 cm and underwent PEIT were enrolled. Therapeutic efficacy, overall and tumor-free survival rates were assessed during follow-up periods. Results: In 83 patients, HCC nodules were completely ablated by PEIT. The cumulative 1, 2, and 3 year overall survival rates were 98%, 96%, and 88%, respectively. The cumulative 1, 2, and 3 year tumor-free survival rates were 73%, 50%, and 37%, respectively. Larger tumors (=2 cm) were associated with a higher local recurrence rate. Conclusions: These results demonstrate that PEIT is therapeutically useful in patients with HCC less than 4 in number and less than 3 cm in diameter. However, since multiple or large tumors are associated with low tumor-free survival or high local recurrence rates, PEIT for these tumors and the subsequent post-treatment follow-up should be performed carefully. (Korean J Gastroenterol 2003;42:502-509)
연구논문 : C형간염바이러스 유전자형 1b에 감염된 한국인 환자에서 인터페론 감수성 결정 영역의 유전자 돌연변이 양상
진영주 ( Young Joo Jin ),박윤경 ( Yoon Kyung Park ),윤귀준 ( Gui Jun Yun ),이한주 ( Han Chu Lee ),정숙향 ( Sook Hyang Jeong ),김강모 ( Gang Mo Kim ),임영석 ( Young Suk Lim ),정영화 ( Young Hwa Chung ),이영상 ( Yung Sang Lee ),서 대한간학회 2010 Clinical and Molecular Hepatology(대한간학회지) Vol.16 No.2
Background/Aims: The treatment response to interferon could differ with mutations in the interferon-sensitivity-determining region (ISDR) in patients infected with hepatitis C virus (HCV) genotype-1b (HCV-Ib). We examined the pattern of ISDR mutations and analyzed whether the number of amino acid substitutions influences the treatment response to peginterferon plus ribavirin in chronic hepatitis or cirrhotic patients infected with HCV-Ib. Methods: The study population comprised 52 patients who visited Seoul Asan Medical Center and Seoul National University Bundang Hospital from January 2006 to December 2008 and who received peginterferon alpha-2a (n=37) or -2b (n=15) plus ribavirin, and whose serum was stored. We analyzed the early virologic response, end-of-treatment response, and sustained virologic response (SVR), and examined the ISDR using direct sequencing. Results: The proportions of patients with ISDR mutation types of wild (0mutations), intermediate (1-3 mutations), and mutant (≥4 mutations) were 50.0%, 42.3%, and 7.7%,respectively, and the corresponding SVR rates were 63%, 50%, and 67% (p>0.05). The SVR rates were 59.4% and 50.0% in patients with <2 and ≥2 mutations, respectively (p>0.05). On univariate analysis, age was the only predictive factor for SVR (p=0.016). The pretreatment HCV RNA titer tended to be lower in those with SVR, but without statistical significance (p=0.069). Conclusions: The frequency of ISDR mutations was low in our cohort of Korean patients infected with HCV-Ib. Therefore, ISDR mutations might not contribute to the response to treatment with peginterferon plus ribavirin.